Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Amortization of Deferred Charges (2021 - 2023)

Historic Amortization of Deferred Charges for Alaunos Therapeutics (TCRT) over the last 3 years, with Q2 2023 value amounting to $867000.0.

  • Alaunos Therapeutics' Amortization of Deferred Charges rose 31884.06% to $867000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $867000.0, marking a year-over-year decrease of 3091.63%. This contributed to the annual value of $1.3 million for FY2023, which is 3649.34% up from last year.
  • Alaunos Therapeutics' Amortization of Deferred Charges amounted to $867000.0 in Q2 2023, which was up 31884.06% from $472000.0 recorded in Q1 2023.
  • Over the past 5 years, Alaunos Therapeutics' Amortization of Deferred Charges peaked at $867000.0 during Q2 2023, and registered a low of $148000.0 during Q3 2021.
  • In the last 3 years, Alaunos Therapeutics' Amortization of Deferred Charges had a median value of $232000.0 in 2021 and averaged $337875.0.
  • As far as peak fluctuations go, Alaunos Therapeutics' Amortization of Deferred Charges skyrocketed by 4765.96% in 2022, and later soared by 31884.06% in 2023.
  • Quarter analysis of 3 years shows Alaunos Therapeutics' Amortization of Deferred Charges stood at $235000.0 in 2021, then surged by 47.66% to $347000.0 in 2022, then surged by 149.86% to $867000.0 in 2023.
  • Its Amortization of Deferred Charges stands at $867000.0 for Q2 2023, versus $472000.0 for Q1 2023 and $347000.0 for Q4 2022.